Chinese red yeast rice food spice inhibits androgen‐dependent and –independent prostate tumor xenograft growth by inhibiting cholesterol biosynthesis in androgen‐dependent and independent prostate cancer

Abstract

Large cohort studies demonstrate that users of cholesterol‐lowering drugs have a reduced risk of prostate cancer. Xenograft studies demonstrate that statins can inhibit prostate cancer (Pca) xenograft growth by depleting lipid raft cholesterol. Chinese Red Yeast Rice (RYR) is a food spice containing a family of monacolins one of which is identical to lovastatin (LV). We have previously demonstrated inhibition of cell proliferation with RYR treatment in human prostate cancer cells in vitro. The present study examined the effects of RYR on growth of androgen‐dependent and androgen‐independent human prostate cancer xenografts in SCID mice. LNCaP and androgen‐independent LNCaP‐AR cells were inoculated subcutaneously in mice receiving LV or 5% RYR diets over 8 wks. RYR inhibited both androgen‐dependent and .independent prostate tumor volume by more than 60 % in SCID mice (P<0.01). RYR showed a more potent effect in reducing tumor size than LV. RYR diet produced lower serum cholesterol and prostate specific antigen levels compared to control and LV in LNCaP‐AR xenograft mice (P<0.05). RYR food spice and nutritional strategies for lowering cholesterol are planned to explore the anti‐cancer activity of RYR and statins in humans. Supported by UCLA CNRU CA 42710 and DOD W81XWH‐07‐1‐0158

Document Details

Document Type
Pub Defense Publication
Publication Date
Mar 01, 2008
Source ID
10.1096/fasebj.22.1_supplement.889.8

Entities

People

  • Aune Moro
  • David Heber
  • Mee Young Hong
  • Navindra P. Seeram
  • Yanjun Zhang

Organizations

  • San Diego State University
  • United States Department of Defense
  • University of California, Los Angeles

Tags

Fields of Study

  • Biology

Readers

  • Climatology
  • Oncology (Cancer Research).
  • Women's Health and Cancer Risk Research: African American Women and Pregnancy Outcomes.